Ciprofloxacin sensitizes hormone-refractory prostate cancer cell lines to doxorubicin and docetaxel treatment on a schedule-dependent manner

Cancer Chemotherapy and Pharmacology

Volumn 64, Issue 3, 2009, Pages 445-454

  Pinto, Ana Catarina ^a,b   Moreira, João Nuno ^a,c   Simões, Sérgio ^a,b,c  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b Bluepharma Pharmaceutical Industry SA   (Portugal)

^c UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Chemosensitization; Ciprofloxacin; Dose reduction index; HRPC; Median effect analysis

Indexed keywords

CIPROFLOXACIN; DOCETAXEL; DOXORUBICIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER HORMONE THERAPY; CANCER RESISTANCE; CELL VIABILITY; CHEMOSENSITIZATION; CONTROLLED STUDY; DRUG POTENTIATION; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; PROSTATE CANCER;

ANTI-INFECTIVE AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CELL SURVIVAL; CIPROFLOXACIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG ANTAGONISM; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; HUMANS; MALE; PROSTATIC NEOPLASMS; TAXOIDS; TIME FACTORS;

EID: 67349257209     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-008-0892-6     Document Type: Article

References (39)

1. VE Anderson RP Zaniewski FS Kaczmarek TD Gootz N Osheroff 1999 Quinolones inhibit DNA religation mediated by Staphylococcus aureus topoisomerase IV. Changes in drug mechanism across evolutionary boundaries J Biol Chem 274 50 35927 35932 (Pubitemid 129512900)
2. O Aranha R Grignon N Fernandes TJ McDonnell DP Wood Jr FH Sarkar 2003 Suppression of human prostate cancer cell growth by ciprofloxacin is associated with cell cycle arrest and apoptosis Int J Oncol 22 4 787 794
3. O Aranha DP Wood Jr FH Sarkar 2000 Ciprofloxacin mediated cell growth inhibition, S/G2-M cell cycle arrest, and apoptosis in a human transitional cell carcinoma of the bladder cell line Clin Cancer Res 6 3 891 900 (Pubitemid 30159346)
4. RP Bakshi S Galande K Muniyappa 2001 Functional and regulatory characteristics of eukaryotic type II DNA topoisomerase Crit Rev Biochem Mol Biol 36 1 1 37 (Pubitemid 32202689)
5. MP Boland KA Fitzgerald LA O'Neill 2000 Topoisomerase II is required for mitoxantrone to signal nuclear factor kappa B activation in HL60 cells J Biol Chem 275 33 25231 25238 (Pubitemid 30687018)
6. DR Budman A Calabro W Kreis 2002 Synergistic and antagonistic combinations of drugs in human prostate cancer cell lines in vitro Anticancer Drugs 13 10 1011 1016 (Pubitemid 36020671)
7. G Capranico M Binaschi 1998 DNA sequence selectivity of topoisomerases and topoisomerase poisons Biochim Biophys Acta 1400 1-3 185 194 (Pubitemid 28475103)
8. TC Chou 1994 Assessment of synergistic and antagonistic effects of chemotherapeutic agents in vitro Contrib Gynecol Obstet 19 91 107
9. TC Chou P Talalay 1983 Analysis of combined drug effects: a new look at a very old problem Trends pharmacol Sci 4 450 454
10. TC Chou P Talalay 1984 Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv Enzyme Regul 22 27 55
11. TC Chou QH Tan FM Sirotnak 1993 Quantitation of the synergistic interaction of edatrexate and cisplatin in vitro Cancer Chemother Pharmacol 31 4 259 264 (Pubitemid 23029148)
12. G Di Lorenzo R Autorino M De Laurentiis R Bianco R Lauria A Giordano M De Sio M D'Armiento AR Bianco S De Placido 2003 Is there a standard chemotherapeutic regimen for hormone-refractory prostate cancer? Present and future approaches in the management of the disease Tumori 89 4 349 360 (Pubitemid 37279914)
13. BF El-Rayes R Grignon N Aslam O Aranha FH Sarkar 2002 Ciprofloxacin inhibits cell growth and synergises the effect of etoposide in hormone resistant prostate cancer cells Int J Oncol 21 1 207 211
14. SH Elsea PR McGuirk TD Gootz M Moynihan N Osheroff 1993 Drug features that contribute to the activity of quinolones against mammalian topoisomerase II and cultured cells: correlation between enhancement of enzyme-mediated DNA cleavage in vitro and cytotoxic potential Antimicrob Agents Chemother 37 10 2179 2186 (Pubitemid 23298208)
15. SH Elsea M Westergaard DA Burden JP Lomenick N Osheroff 1997 Quinolones share a common interaction domain on topoisomerase II with other DNA cleavage-enhancing antineoplastic drugs Biochemistry 36 10 2919 2924 (Pubitemid 27138575)
16. W Fan KR Johnson MC Miller 3rd 1998 In vitro evaluation of combination chemotherapy against human tumor cells (Review) Oncol Rep 5 5 1035 1042 (Pubitemid 28372557)
17. DA Gewirtz 1999 A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin Biochem Pharmacol 57 7 727 741 (Pubitemid 29094544)
18. MA Gonzalez F Uribe SD Moisen AP Fuster A Selen PG Welling B Painter 1984 Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers Antimicrob Agents Chemother 26 5 741 744 (Pubitemid 15211673)
19. S Goodin KV Rao RS DiPaola 2002 State-of-the-art treatment of metastatic hormone-refractory prostate cancer Oncologist 7 4 360 370 (Pubitemid 34919960)
20. KA Harris E Harney EJ Small 2002 Liposomal doxorubicin for the treatment of hormone-refractory prostate cancer Clin Prostate Cancer 1 1 37 41 (Pubitemid 37045885)
21. GN Hortobagyi 1997 Anthracyclines in the treatment of cancer. An overview Drugs 54 Suppl 4 1 7 (Pubitemid 27487789)
22. TC Hour J Chen CY Huang JY Guan SH Lu YS Pu 2002 Curcumin enhances cytotoxicity of chemotherapeutic agents in prostate cancer cells by inducing p21(WAF1/CIP1) and C/EBPbeta expressions and suppressing NF-kappaB activation Prostate 51 3 211 218 (Pubitemid 34492642)
23. A Hubert O Lyass D Pode A Gabizon 2000 Doxil (Caelyx): an exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer Anticancer Drugs 11 2 123 127 (Pubitemid 30193068)
24. ML Immordino P Brusa S Arpicco B Stella F Dosio L Cattel 2003 Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel J Control Release 91 3 417 429 (Pubitemid 36980659)
25. AM Kamat JI DeHaven DL Lamm 1999 Quinolone antibiotics: a potential adjunct to intravesical chemotherapy for bladder cancer Urology 54 1 56 61 (Pubitemid 29323333)
26. SH Kaufmann D Peereboom CA Buckwalter PA Svingen LB Grochow RC Donehower EK Rowinsky 1996 Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines J Natl Cancer Inst 88 11 734 741 (Pubitemid 26195021)
27. W Kreis DR Budman A Calabro 2001 A reexamination of PSC 833 (Valspodar) as a cytotoxic agent and in combination with anticancer agents Cancer Chemother Pharmacol 47 1 78 82 (Pubitemid 32664517)
28. NJ Mackler KJ Pienta 2005 Drug insight: Use of docetaxel in prostate and urothelial cancers Nat Clin Pract Urol 2 2 92 100 quiz 101 p following 112 (Pubitemid 40790129)
29. H Malonne G Atassi 1997 DNA topoisomerase targeting drugs: mechanisms of action and perspectives Anticancer Drugs 8 9 811 822 (Pubitemid 27487794)
30. KG Naber F Sorgel F Kees U Jaehde H Schumacher 1989 Pharmacokinetics of ciprofloxacin in young (healthy volunteers) and elderly patients, and concentrations in prostatic fluid, seminal fluid, and prostatic adenoma tissue following intravenous administration Am J Med 87 5A 57S 59S (Pubitemid 20005146)
31. J O'Brien I Wilson T Orton F Pognan 2000 Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity Eur J Biochem 267 17 5421 5426 (Pubitemid 30679258)
32. MJ Robinson BA Martin TD Gootz PR McGuirk M Moynihan JA Sutcliffe N Osheroff 1991 Effects of quinolone derivatives on eukaryotic topoisomerase II. A novel mechanism for enhancement of enzyme-mediated DNA cleavage J Biol Chem 266 22 14585 14592 (Pubitemid 21907543)
33. S Simoes V Slepushkin P Pires R Gaspar MP de Lima N Duzgunes 1999 Mechanisms of gene transfer mediated by lipoplexes associated with targeting ligands or pH-sensitive peptides Gene Ther 6 11 1798 1807 (Pubitemid 29531275)
34. G Sonpavde TE Hutson WR Berry 2006 Hormone refractory prostate cancer: management and advances Cancer Treat Rev 32 2 90 100 (Pubitemid 43362230)
35. JP van Brussel GJ van Steenbrugge JC Romijn FH Schroder GH Mickisch 1999 Chemosensitivity of prostate cancer cell lines and expression of multidrug resistance-related proteins Eur J Cancer 35 4 664 671 (Pubitemid 29192979)
36. GL Wampler WH Carter Jr ED Campbell PA Keefe 1992 Relationships between various uses of antineoplastic drug-interaction terms Cancer Chemother Pharmacol 31 2 111 117
37. MG Wientjes JH Zheng L Hu Y Gan JL Au 2005 Intraprostatic chemotherapy: distribution and transport mechanisms Clin Cancer Res 11 11 4204 4211 (Pubitemid 40796134)
38. S Zeng YZ Chen L Fu KR Johnson W Fan 2000 In vitro evaluation of schedule-dependent interactions between docetaxel and doxorubicin against human breast and ovarian cancer cells Clin Cancer Res 6 9 3766 3773 (Pubitemid 30694963)
39. W Zoli L Ricotti A Tesei F Barzanti D Amadori 2001 In vitro preclinical models for a rational design of chemotherapy combinations in human tumors Crit Rev Oncol Hematol 37 1 69 82 (Pubitemid 32063319)